CN Patent

CN112262130B — 奥德昔巴特的结晶修饰物

Assigned to Albireo AB · Expires 2024-07-02 · 2y expired

What this patent protects

本发明涉及1,1‑二氧代‑3,3‑二丁基‑5‑苯基‑7‑甲硫基‑8‑(N‑{(R)‑α‑[N‑((S)‑1‑羧丙基)氨甲酰基]‑4‑羟基苯甲基}氨甲酰基甲氧基)‑2,3,4,5‑四氢‑1,2,5‑苯并硫杂二氮杂 (奥德昔巴特)(odevixibat)的结晶修饰物，更特别是奥德昔巴特的结晶修饰物和2。本发明还涉及一种制备奥德昔巴特的结晶修饰物1的方法，一种包含结晶修饰物1的药物组合物，及此结晶修饰物治疗如本文所述的各种病症的用途。

USPTO Abstract

本发明涉及1,1‑二氧代‑3,3‑二丁基‑5‑苯基‑7‑甲硫基‑8‑(N‑{(R)‑α‑[N‑((S)‑1‑羧丙基)氨甲酰基]‑4‑羟基苯甲基}氨甲酰基甲氧基)‑2,3,4,5‑四氢‑1,2,5‑苯并硫杂二氮杂 (奥德昔巴特)(odevixibat)的结晶修饰物，更特别是奥德昔巴特的结晶修饰物和2。本发明还涉及一种制备奥德昔巴特的结晶修饰物1的方法，一种包含结晶修饰物1的药物组合物，及此结晶修饰物治疗如本文所述的各种病症的用途。

Drugs covered by this patent

Patent Metadata

Patent number
CN112262130B
Jurisdiction
CN
Classification
—
Expires
2024-07-02
Drug substance claim
No
Drug product claim
No
Assignee
Albireo AB
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.